Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric‐Bernstam, John D. Hainsworth, Steven Blotner et al.|The Lancet Oncology|2019Cited by 564
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Maria Di Bartolomeo et al.|The Lancet Oncology|2021Cited by 411
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping PanelJason Willis, Justin I. Odegaard, Martina I. Lefterova et al.|Clinical Cancer Research|2019Cited by 237
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerTakayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav et al.|Nature Communications|2023Cited by 159
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).Marwan Fakih, Andrew Scott Paulson, Kanwal Raghav et al.|Journal of Clinical Oncology|2021Cited by 74